Neose Technologies begins phase 1 trial of NE-180 anemia drug

By Angela McDaniels

Seattle, Feb. 13 - Neose Technologies Inc. said it has begun dosing healthy volunteers in a phase 1 clinical trial of NE-180, the company's long-acting, GlycoPEGylated erythropoietin for the treatment of anemia.

The open-label, ascending dose trial is being conducted in Western Europe and will evaluate the safety and pharmacokinetics of NE-180 in roughly 40 volunteers. The drug will be given both subcutaneously and intravenously.

If the trial results demonstrate that single ascending doses are safe and well tolerated, Neose said it will begin a multiple-dose phase 2a trial in the second half of 2006.

"The initiation of dosing in our phase 1 trial for NE-180 marks an important milestone for Neose. NE-180 is the first of the company's long-acting therapeutic proteins to enter clinical development," president and chief operating officer George J. Vergis said in a company news release.

Neose is a biopharmaceutical company based in Horsham, Pa., that uses its proprietary enzymatic technologies to develop improved drugs, primarily therapeutic proteins.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.